What is the impact factor of Nature Medicine?

Nature Medicine has an impact factor of 50.0 (2024). This places it among the top-tier journals in its field with Nature Medicine occupies the most valuable real estate in biomedical publishing: the space between Cell's mechanistic depth and NEJM's clinical rigor.

How long does Nature Medicine take to review?

Nature Medicine typically takes ~30 days to first decision. The full review process involves 6 main stages: presubmission inquiry (recommended for scope uncertainty), full manuscript submission, and peer review.

How much does it cost to publish in Nature Medicine?

Nature Medicine charges ~$11,690 USD as an article processing charge. Institutional Springer Nature agreements may cover

All Journal Guides

Journal Guide

Nature Medicine Impact Factor 50.0: Publishing Guide

Q: What is the acceptance rate of Nature Medicine?

Nature Medicine has an acceptance rate of <8%. A common reason for rejection is submitting mouse studies without human validation. Nature Medicine's editorial team explicitly states that mouse-only translational studies no longer meet their standard. At minimum, you need human samples - patient biopsies, organoids, primary cells, clinical data - demonstrating that the mechanism is present and relevant in humans. If you don't have human data yet, the paper belongs at a journal with a lower human-data bar while you generate the validation.

Q: Is Nature Medicine peer reviewed?

Yes, Nature Medicine is fully peer reviewed. All submissions undergo rigorous peer review by 2-3 reviewers spanning basic research and clinical expertise in the relevant disease area. Both the mechanistic rigor and the clinical relevance are assessed. Reviewers frequently request additional human validation data, independent cohort replication, or therapeutic proof-of-concept experiments. Expect substantive revision requests in the first round..

Q: What does Nature Medicine look for in submissions?

The translational bridge - mechanism plus human relevance: Pure basic science belongs in Cell or Nature. Pure clinical trials belong in NEJM or Lancet. Nature Medicine wants the connection: basic discovery validated in human data, or clinical observation explained by mechanistic insight. If your paper has only one side of this bridge, it belongs in a different journal. The classic Nature Medicine paper has a mechanistic story in model systems plus validation in patient samples plus either a therapeutic demonstration or a clear clinical implication.

Q: What should I know before submitting to Nature Medicine?

Nature Medicine is the primary venue for translational biotech research. Company-sponsored translational research - cell therapy clinical trials, gene editing in vivo, targeted protein degradation - fits Nature Medicine better than Cell or Nature, which can be skeptical of industry ties. Full COI disclosure is required and transparency is expected, but the work is welcome.

Where basic science becomes medicine: the bridge from bench to bedside

50.0

Impact Factor (2024)

<8%

Acceptance Rate

~30 days to first decision

Time to First Decision

What Nature Medicine Publishes

Nature Medicine occupies the most valuable real estate in biomedical publishing: the space between Cell's mechanistic depth and NEJM's clinical rigor. Founded in 1995 and published by Springer Nature, it publishes research that connects basic biological discovery to human health - translational science where the mechanism matters and the patient relevance is explicit. An impact factor consistently above 50 makes it one of the highest-impact journals in all of medicine and biology combined. The editorial standard is high and the competition is intense: ~4,000 submissions per year for fewer than 300 published papers. The defining criterion is the translational bridge - does your work move something from bench toward bedside, or from bedside back to bench to explain a clinical observation? If yes, Nature Medicine is the right target. If your work is mechanistic without disease relevance, consider Cell or Nature. If it is clinical without mechanistic insight, consider NEJM or Lancet.

Translational research where basic mechanistic discovery is directly connected to human disease biology - papers that establish a mechanism and demonstrate its relevance in human samples or patient data
First-in-human clinical trials of novel therapeutic approaches, particularly where the mechanism of action is characterized and the therapeutic strategy is genuinely new
Biomarker discovery and clinical validation - liquid biopsy, imaging biomarkers, multi-omic patient stratification, predictive and prognostic signatures validated in patient cohorts
Disease mechanism studies where the molecular or cellular finding has clear therapeutic implications - not just 'X causes disease' but 'X causes disease and blocking X with Y is feasible'
Precision medicine studies integrating genomic, proteomic, or metabolomic data with clinical outcomes to enable patient stratification or treatment selection
Machine learning and AI applied to clinical prediction, drug discovery, or medical imaging - with clinical validation in real patient populations, not just benchmark datasets
Large patient cohort studies with deep molecular phenotyping that reveal disease subtypes, progression mechanisms, or treatment response predictors

Editor Insight

“Nature Medicine lives in the translational space. The question is always: does this advance our understanding of human disease, and does that understanding point toward better treatment? Pure mechanism without disease relevance belongs elsewhere. Pure clinical outcomes without mechanistic insight also belongs elsewhere.”

What Nature Medicine Editors Look For

The translational bridge - mechanism plus human relevance

Pure basic science belongs in Cell or Nature. Pure clinical trials belong in NEJM or Lancet. Nature Medicine wants the connection: basic discovery validated in human data, or clinical observation explained by mechanistic insight. If your paper has only one side of this bridge, it belongs in a different journal. The classic Nature Medicine paper has a mechanistic story in model systems plus validation in patient samples plus either a therapeutic demonstration or a clear clinical implication.

Human data - the bar has risen dramatically

Mouse-only translational studies rarely reach peer review at Nature Medicine anymore. You need human samples, patient-derived organoids, clinical data, or a direct demonstration of human relevance. The 'but it will be relevant to humans' argument is not sufficient. Human samples are not an afterthought - they are now a requirement. Plan your study to include them from the beginning, or position the work for a different journal.

Therapeutic implications beyond 'could be druggable'

Understanding a disease mechanism is the starting point, not the finish line. Nature Medicine wants to see what you can do with the knowledge: a therapeutic proof of concept, a drug target validation, a biomarker for treatment selection, or a clinical intervention study. Papers that identify a mechanism and conclude with 'this suggests X could be a therapeutic target' without testing it face skepticism. Show the therapeutic angle, don't just assert it.

Technical rigor at every level of the study

If your paper spans molecular work, animal models, and clinical data, every level must be rigorous. The most common Nature Medicine review complaint is that one component of a multi-level study is significantly weaker than the others - often the clinical validation is thin while the mechanistic work is deep, or the mechanistic story is vague while the clinical dataset is large. Reviewers notice and flag imbalances.

Novel therapeutic strategies over confirmation of existing ones

Nature Medicine is particularly interested in genuinely new therapeutic approaches: first-in-class mechanisms, repurposing with mechanistic justification, combination strategies based on pathway insights, or novel delivery or targeting methods. Confirmatory studies of approaches that already have Phase 3 data belong in clinical journals, not Nature Medicine.

Reproducibility across cohorts and approaches

Given the translational reproducibility crisis in biomedical research, Nature Medicine editors are attuned to single-cohort findings that haven't been replicated. Two independent patient cohorts, orthogonal experimental approaches validating the same conclusion, and pre-specified validation analyses are viewed favorably. Findings from a single institution's patient data without replication face heightened scrutiny.

Why Papers Get Rejected

These patterns appear repeatedly in manuscripts that don't make it past Nature Medicine's editorial review:

Submitting mouse studies without human validation

Nature Medicine's editorial team explicitly states that mouse-only translational studies no longer meet their standard. At minimum, you need human samples - patient biopsies, organoids, primary cells, clinical data - demonstrating that the mechanism is present and relevant in humans. If you don't have human data yet, the paper belongs at a journal with a lower human-data bar while you generate the validation.

Clinical data without mechanistic insight

A randomized controlled trial showing that treatment A works better than treatment B is a NEJM or Lancet paper. Nature Medicine wants to know why it works. If you have excellent clinical trial data but no mechanistic story, submit to the appropriate clinical journal. If you add a mechanistic substudy - even relatively small - that explains the mechanism, the paper may become appropriate for Nature Medicine.

Handwaving about therapeutic potential

Papers that identify a disease mechanism and conclude with 'this pathway could be targeted therapeutically' without any therapeutic data are consistently flagged. Reviewers at Nature Medicine expect at least a proof-of-concept demonstration that the mechanism is actionable - a preclinical drug study, a genetic knockdown with phenotypic rescue, or a small cohort pharmacological intervention.

Single-patient anecdotes or case series

Even for rare diseases, Nature Medicine expects systematic data from defined patient populations. Extraordinary individual cases may be appropriate for NEJM Case Records or similar formats, not for Nature Medicine Research Articles. If your compelling single-case observation is accompanied by systematic mechanistic characterization and independent validation in other patients, it may be appropriate - but the anecdote alone is not.

Ignoring reproducibility and validation standards

The translational reproducibility crisis has made Nature Medicine editors particularly attentive to single-lab, single-cohort, single-approach findings. Multiple orthogonal lines of evidence, independent validation cohorts, and pre-specified analyses strengthen submissions substantially. Post-hoc analyses without pre-specification are flagged.

Submitting industry-funded work without transparent disclosure

Nature Medicine publishes industry-sponsored research, but competing interests must be fully disclosed and the editorial team scrutinizes whether commercial relationships may have influenced conclusions. Data access, author control of analysis, and independent statistical review must be documented. Incomplete disclosure is grounds for rejection after acceptance.

Does your manuscript avoid these patterns?

The quick diagnostic reads your full manuscript against Nature Medicine's criteria and flags the specific issues most likely to cause rejection.

Run Free Readiness Scan →

Insider Tips from Nature Medicine Authors

Nature Medicine is the primary venue for translational biotech research

Company-sponsored translational research - cell therapy clinical trials, gene editing in vivo, targeted protein degradation - fits Nature Medicine better than Cell or Nature, which can be skeptical of industry ties. Full COI disclosure is required and transparency is expected, but the work is welcome.

Phase 1 first-in-human data is publishable here - you don't need Phase 3

Unlike NEJM or Lancet, which require definitive late-phase trial results, Nature Medicine will publish Phase 1 or first-in-human studies if they demonstrate a genuinely novel therapeutic concept with mechanistic characterization. If you are the first to treat a disease with a new modality, Nature Medicine is interested even without efficacy data.

Biomarker validation is a strong content category

If you have discovered a biomarker - circulating tumor DNA, protein signature, imaging feature, or multi-omic score - that predicts response, enables patient stratification, or enables precision medicine decisions, Nature Medicine is a natural fit. The key is validation: one discovery cohort is not enough. Two independent validation cohorts significantly strengthen the paper.

AI and machine learning papers must include prospective or clinical validation

Nature Medicine has published important AI/ML papers in medical imaging, drug discovery, and clinical prediction. The bar is clinical validation in real patients, not just benchmark datasets. A model that outperforms pathologists on held-out slides from the same institution is insufficient. Independent validation in a different institution's data or a prospective study is expected.

The Nature family transfer system actively routes papers

Nature Medicine often receives transfers from Nature (too translational for the flagship) or refers papers to Nature Communications or other family journals when the work is strong but not Nature Medicine-level. These transfers include reviewer comments, which can substantially accelerate the review process at the receiving journal.

Resource papers for large patient datasets are a real pathway

If you have generated a large, deeply characterized patient cohort, biobank, single-cell atlas of disease tissue, or reference dataset for a major disease, Nature Medicine publishes these as Resource papers. The resource itself must be publicly accessible and the biological insights from it must be substantial.

Immunotherapy and gene therapy are intensely competitive

Cancer immunotherapy, CAR-T, gene editing, and mRNA therapeutics are active areas at Nature Medicine with very high submission rates. Competition is intense and the bar for novelty is high. If you are in these spaces, position your work carefully against what has already been published and what is likely on bioRxiv from competing groups.

Preprints are now accepted and encouraged

Nature Medicine's policy on preprints changed during COVID-19 and is now permanent. You can post a preprint on bioRxiv or medRxiv immediately upon submission without jeopardizing editorial consideration. This is now standard practice in fast-moving translational fields.

The Nature Medicine Submission Process

Presubmission inquiry (recommended for scope uncertainty)

Response within 1-2 weeks

If you are unsure whether your work fits Nature Medicine vs. Nature, Cell, or a clinical journal, submit a 1-page inquiry: the disease question, key finding, human validation data summary, and therapeutic implication. Editors respond within 1-2 weeks. This is particularly valuable for papers at the boundary between basic science and clinical translation.

Full manuscript submission

Day 1

Submit via the Nature Medicine submission portal. Prepare a complete manuscript with cover letter explicitly articulating the translational bridge - what basic discovery connects to what human health implication. Figures should include both mechanistic data and human validation data. Full COI disclosure is required for all authors, particularly those with industry affiliations. Data availability statement must specify where datasets are deposited.

Editorial assessment

2-3 weeks

Editors assess translational relevance, novelty, human data sufficiency, and scope fit. About 60% of submissions are desk rejected. Common reasons: insufficient human data, pure basic science without disease connection, pure clinical trial without mechanistic insight, overlap with recently published work. Editors may suggest transfer to Nature Communications or a specialty journal if the work is strong but doesn't meet Nature Medicine's translational standard.

Peer review

4-6 weeks after reviewer assignment

2-3 reviewers spanning basic research and clinical expertise in the relevant disease area. Both the mechanistic rigor and the clinical relevance are assessed. Reviewers frequently request additional human validation data, independent cohort replication, or therapeutic proof-of-concept experiments. Expect substantive revision requests in the first round.

Revision

Variable; depends on scope of additional experiments required

Major revisions often require additional human patient samples, independent cohort validation, or new experimental data. Revision timelines depend on the scope of requested work - minor manuscript revisions in 30-60 days; major experiments requiring new patient recruitment may take 6-12 months. Editors are available to discuss whether specific requested experiments are necessary before you commit to them.

Acceptance and publication

2-3 weeks from acceptance to online publication

Accepted papers are published online within 2-3 weeks of final acceptance. High-impact papers receive press embargo coordination and may be featured in Nature Medicine's editorial or perspective section. Preprint versions on bioRxiv/medRxiv are updated with the final published version automatically through the Nature Linking Service.

Nature Medicine by the Numbers

2024 Impact Factor(Clarivate JCR 2024 - one of the highest in all of medicine)	58.7
CiteScore (Scopus)	90.0
Submissions per year	~4,000
Acceptance rate	<8%
Desk rejection rate	~60%
Post-review acceptance	~40% of reviewed manuscripts
Time to first decision	~30 days
Publication frequency	Monthly, 12 issues/year
Open access APC(Institutional Springer Nature agreements may cover)	~$11,690 USD
Founded(Springer Nature)	1995

Before you submit

Nature Medicine accepts a small fraction of submissions. Make your attempt count.

The pre-submission diagnostic runs a live literature search, scores your manuscript section by section, and gives you a prioritized fix list calibrated to Nature Medicine. ~30 minutes.

Run Free Readiness Scan See a sample report

Article Types

Article

~5,000 words main text; Methods separate

Full translational research reports presenting complete mechanistic and human-relevance data. The primary content type. No strict word limit but conciseness is valued. Methods section does not count toward main text. Multiple display items and Extended Data figures permitted for complex multi-level studies.

Brief Communication

~2,000-3,000 words

Shorter reports of significant translational findings where the evidence is focused and the finding is important enough to warrant rapid communication. Same standard as Articles but compressed format. Appropriate for phase 1 trials with compelling mechanism data or focused biomarker discoveries.

Resource

Variable

Large patient cohorts, disease tissue atlases, single-cell datasets, clinical biobanks, or reference datasets with substantial biological insights derived from them. The resource must be publicly accessible and the analysis must reveal novel biology, not just confirm existing knowledge.

Perspective

~2,000-3,000 words

Forward-looking commentary on emerging therapeutic strategies, clinical trial design, or translational research frameworks - almost always invited. Unsolicited Perspectives are occasionally considered from recognized leaders in a field.

Landmark Nature Medicine Papers

Papers that defined fields and changed science:

Neurogenesis in the adult human hippocampus (Eriksson et al., 1998)
Cancer stem cell hierarchy in human acute myeloid leukemia (Bonnet & Dick, 1997)
Tumor-associated B7-H1/PD-L1 promotes T-cell apoptosis and immune evasion (Dong et al., 2002)
Two-year semaglutide weight loss in obesity - STEP 5 trial (Garvey et al., 2022)
First in vivo CRISPR gene editing for transthyretin amyloidosis (Gillmore et al., 2021)

Preparing a Nature Medicine Submission?

Get pre-submission feedback from reviewers who've published in Nature Medicine and know exactly what editors look for.

Run Free Readiness Scan

Need expert depth? Human review from $1,000

NDA-protected

Confidential

Primary Fields

Translational MedicineCancerImmunologyNeurologyCardiologyMetabolic DiseaseRare DiseasesGene & Cell Therapy

Ready to submit to Nature Medicine?

A desk rejection costs months. Get expert feedback before you submit, from scientists who know exactly what Nature Medicine editors look for.

Need field-expert depth? Human review from $1,000